Chidamide has higher anti‐tumor activity in TP53‐mutant DLBCL cells compared to TP53‐wildtype DLBCL cells and reduced the mRNA and protein levels of mutant TP53 [31]. Here, TP53 is linked to diffuse large B-cell lymphoma.